Fourth quarter and full-year 2020


Sanofi delivered close to double digit Q4 2020 business EPS growth at CER

Fourth quarter and full-year 2020 results were reviewed by management during a live audio webcast with the financial community.
Fourth quarter and full-year 2020 results were followed by a virtual Capital Markets Day (CMD21).

I am incredibly proud of the measurable progress we made in 2020 even in the face of a global pandemic. We'll stay the course in 2021, focused on bringing breakthrough medicines and vaccines to people around the world.

Paul Hudson

Chief Executive Officer



Press release

Q4 and FY 2020 income statements, cash flow statements, balance sheet

Q4 and FY 2020 net sales by GBU, franchise, geographic region and product

Clinical trials appendices

Download infographic

Q4 2020 Memorandum for modelling purposes